196 related articles for article (PubMed ID: 26143637)
1. pHLIP-mediated targeting of truncated tissue factor to tumor vessels causes vascular occlusion and impairs tumor growth.
Li S; Tian Y; Zhao Y; Zhang Y; Su S; Wang J; Wu M; Shi Q; Anderson GJ; Thomsen J; Zhao R; Ji T; Wang J; Nie G
Oncotarget; 2015 Sep; 6(27):23523-32. PubMed ID: 26143637
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
[TBL] [Abstract][Full Text] [Related]
3. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
5. Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction.
Shi Q; Zhang Y; Liu S; Liu G; Xu J; Zhao X; Anderson GJ; Nie G; Li S
Biochem Pharmacol; 2018 Oct; 156():501-510. PubMed ID: 30222966
[TBL] [Abstract][Full Text] [Related]
6. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis.
Hu P; Yan J; Sharifi J; Bai T; Khawli LA; Epstein AL
Cancer Res; 2003 Aug; 63(16):5046-53. PubMed ID: 12941833
[TBL] [Abstract][Full Text] [Related]
7. Generation of fusion proteins for selective occlusion of tumor vessels.
Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
[TBL] [Abstract][Full Text] [Related]
8. [Humanized monoclonal antibody TNT-3-mediated truncated tissue factor for the treatment of H22 hepatoma-bearing mice].
Huang ZJ; Wang R; Liu ZZ; Wang SY; Yan JH; Luo Q
Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):249-53. PubMed ID: 22781034
[TBL] [Abstract][Full Text] [Related]
9. Metabonomic Investigation of Biological Effects of a New Vessel Target Protein tTF-pHLIP in a Mouse Model.
Ding L; Zhang C; Liu Z; Huang Q; Zhang Y; Li S; Nie G; Tang H; Wang Y
J Proteome Res; 2020 Jan; 19(1):238-247. PubMed ID: 31603327
[TBL] [Abstract][Full Text] [Related]
10. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
[TBL] [Abstract][Full Text] [Related]
11. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
[TBL] [Abstract][Full Text] [Related]
12. Construction of novel procoagulant protein targeting neuropilin-1 on tumour vasculature for tumour embolization therapy.
Zou M; Samiullah M; Xu P; Wang S; He J; Wu T; Luo F; Yan J
J Drug Target; 2019 Sep; 27(8):885-895. PubMed ID: 30628471
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
[TBL] [Abstract][Full Text] [Related]
14. Tissue-factor fusion proteins induce occlusion of tumor vessels.
Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
[TBL] [Abstract][Full Text] [Related]
15. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
[TBL] [Abstract][Full Text] [Related]
16. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
[TBL] [Abstract][Full Text] [Related]
17. Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels.
Xu P; Zou M; Wang S; Wang L; Wang L; Luo F; Wu T; Yan J
Anticancer Drugs; 2019 Jun; 30(5):441-450. PubMed ID: 30807552
[TBL] [Abstract][Full Text] [Related]
18. Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: preparation, characterization and double targeting.
Chen X; Lv H; Ye M; Wang S; Ni E; Zeng F; Cao C; Luo F; Yan J
Int J Pharm; 2012 Apr; 426(1-2):248-255. PubMed ID: 22310463
[TBL] [Abstract][Full Text] [Related]
19. Virus-Inspired Gold Nanorod-Mesoporous Silica Core-Shell Nanoparticles Integrated with tTF-EG3287 for Synergetic Tumor Photothermal Therapy and Selective Therapy for Vascular Thrombosis.
Luo X; Xie J; Zhou Z; Ma S; Wang L; Li M; Liu J; Wang P; Li Y; Luo F; Yan J
ACS Appl Mater Interfaces; 2021 Sep; 13(37):44013-44027. PubMed ID: 34494427
[TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of a truncated tissue factor‑coagulation‑based composite system for selective thrombosis in tumor blood vessels.
Xu P; Zou M; Wang S; Li T; Liu C; Wang L; Wang L; Luo F; Wu T; Yan J
Int J Oncol; 2019 Oct; 55(4):823-832. PubMed ID: 31432158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
